| Autor: |
Raaijmakers, H.G.P., Izquierdo, M.A.I., Lokhorst, H.M., de Leeuw, C., Belien, J.A.M., Bloem, A.C., Dekker, A.W., Scheper, R.J., Sonneveld, P. |
| Zdroj: |
Blood; February 1998, Vol. 91 Issue: 3 p1029-1036, 8p |
| Abstrakt: |
This study was undertaken to assess the significance of lung-resistance related protein (LRP) expression in plasma cells from untreated multiple myeloma (MM) patients and to determine whether LRP was associated with a poor response and survival in patients treated with different dose regimens of melphalan. Seventy untreated patients received conventional oral dose melphalan (0.25 mg/kg, day 1 to 4) combined with prednisone (MP) or intravenous intermediate-IDM; 70 mg/m2) or high- (140 mg/m2) dose Melphalan (HDM). LRP expression was assessed with immunocytochemistry using the LRP-56 monoclonal antibody. LRP expression was found in 47% of patients. In the MP treated patients, LRP expression was a significant prognostic factor regarding response induction (P?
|
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
